
LIB Therapeutics shared new results on LEROCHOL at the ACC 2026 meeting in New Orleans (March 28–29, 2026)
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026 LIB Therapeutics Inc. a privately-held, biopharmaceutical company with a recently approved novel, monthly, small dose third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced…












